1
|
Varma PP, Raman DK, Ramakrishnan TS, Singh P. Prevalence of Early Stages of Chronic Kidney Disease in Healthy Army Personnel. Med J Armed Forces India 2011; 67:9-14. [PMID: 27365754 PMCID: PMC4920611 DOI: 10.1016/s0377-1237(11)80004-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2010] [Accepted: 12/01/2010] [Indexed: 01/15/2023] Open
Abstract
INTRODUCTION Chronic kidney disease (CKD) is associated with significant morbidity and mortality. Screening and detection of early stages of CKD can help institute interventions that may delay the progression of the disease. One aim was to study the prevalence of early stages of CKD in the Army. METHODS A cross-sectional study of Army Personnel in an Army cantt in Central India was carried out. All participants filled a structured questionnaire and anthropometric data was collected. Investigative profile included routine urine exam, semi-quantitative microalbuminuria (MAU), serum creatinine, lipid profile and fasting blood glucose. Glomerular Filteration rate (eGFR) was calculated using the Modification of Diet in Renal Diseases (MDRD) study equation. RESULT A total of 1920 subjects were examined with 731 (38.07%) from Arms and 1189 (61.93%) from Services. 348 were excluded and of the remaining 1572 subjects, 141 (8.97 %) had MAU and 157 (9.99 %) had deranged Albumin Creatinine Ratio (ACR). Mean eGFR by MDRD equation was 102 ± 25.84 ml/min/1.73m (2) . Early CKD was seen in 150 (9.54 %) with 84 (5.34 %) in stage I CKD, 55 (3.5%) in stage II and 11 (0.7%) in stage III. Multiple logistic regression showed BMI > 23, the presence of DM and HTN were independent risk factors for CKD. CONCLUSION 9.54% of healthy army personnel were found to have early stages of CKD. Institution of screening programs can result in early detection of CKD.
Collapse
Affiliation(s)
- PP Varma
- Dy Commandant, Army Hospital (R&R), Delhi Cantt-10
| | - DK Raman
- Classified Specialist (Pathology), Base Hospital, Delhi Cantt
| | | | | |
Collapse
|
2
|
Shankar A, Klein R, Klein BEK, Nieto FJ, Moss SE. Relationship Between Low-Normal Blood Pressure and Kidney Disease in Type 1 Diabetes. Hypertension 2007; 49:48-54. [PMID: 17130303 DOI: 10.1161/01.hyp.0000252431.75154.3a] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Current recommendations, largely based on studies in type 2 diabetes, suggest lower target blood pressures (BPs) for individuals with diabetes than for the general population. However, the effect of lower BP on renal outcomes in type 1 diabetes is uncertain. In a population-based cohort of type 1 diabetes adults (mean age: 33.1 years) based in Wisconsin, of which the distribution of baseline BP was in the low-normal range, we examined the relationship between decreasing categories of systolic and diastolic BP and the 16-year incidence of proteinuria (n=232 of 604) and estimated glomerular filtration rate of <60 mL/min/1.73 m
2
(n=158 of 547). Decreasing BP categories had lower relative risk (RR) of developing incident proteinuria (RR comparing decreasing quartiles of systolic BP: 1.00, 0.76, 0.58, 0.73;
P
for trend=0.03; RR comparing decreasing quartiles of diastolic BP: 1.00, 0.81, 0.66, 0.42;
P
for trend <0.0001) and incident estimated glomerular filtration rate <60 mL/min/1.73 m
2
(RR comparing decreasing quartiles of systolic BP: 1.00, 0.83, 0.61, 0.65;
P
for trend=0.03; RR comparing decreasing quartiles of diastolic BP: 1.00, 0.84, 0.82, 0.43;
P
for trend=0.001). These associations were independent of glycemic control and several putative confounding factors. Subjects with either systolic BP <120 mm Hg or diastolic BP <70 mm Hg had significantly lower RR (95% confidence interval) of incident proteinuria (0.63 [0.48 to 0.82]) and incident estimated glomerular filtration rate <60 mL/min/1.73 m
2
(0.60 [0.43 to 0.82]); corresponding population-attributable risks for these outcomes were 26.7% and 29.5%, respectively. Our study suggests that lower BP levels, even below the accepted normal range, are protective against kidney disease in adults with type 1 diabetes. Interventional trials are desirable to clarify the clinical significance of this association.
Collapse
Affiliation(s)
- Anoop Shankar
- Department of Community, Occupational, and Family Medicine, National University of Singapore, 16 Medical Dr, Singapore 117597.
| | | | | | | | | |
Collapse
|
3
|
Dong FB, Sorensen SW, Manninen DL, Thompson TJ, Narayan V, Orians CE, Gregg EW, Eastman RC, Dasbach EJ, Herman WH, Newman JM, Narva AS, Ballard DJ, Engelgau MM. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus. PHARMACOECONOMICS 2004; 22:1015-1027. [PMID: 15449965 DOI: 10.2165/00019053-200422150-00005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
OBJECTIVE Current guidelines recommend treating patients with type 1 diabetes mellitus with ACE inhibitors after the onset of microalbuminuria. Recent clinical trials have shown ACE inhibitors can affect the development of nephropathy when initiated prior to the onset of microalbuminuria. Our objective is to examine the cost effectiveness of treating adults aged over 20 years with an ACE inhibitor (captopril) immediately following diagnosis of type 1 diabetes versus treating them after the onset of microalbuminuria. DESIGN Using a semi-Markov model, we calculated four main outcome measures: lifetime direct medical costs (discounted), QALYs, cumulative incidence of end-stage renal disease (ESRD), and number of days of ESRD over a lifetime. Medical costs are in 1999 US dollars. SETTING All analyses were from the viewpoint of a single US payer responsible for all direct medical costs, including screening for microalbuminuria, ACE inhibitor treatment (captopril), management of major diabetic complications, and routine annual medical costs not specific to diabetes. METHODS We applied the model to a hypothetical cohort of 10,000 persons newly diagnosed with type 1 diabetes. Distribution of sex and race/ethnicity within the cohort is representative of the general US population. RESULTS We estimated that the incremental cost of early use of captopril for the average adult with type 1 diabetes is USD 27,143 per QALY. This level varies considerably with age and glycaemic level. When the age at onset of diabetes is 20 years and glycosylated haemoglobin (HbA(1c)) level is 9%, the cost-effectiveness ratio is USD 13,814 per QALY. When the age at onset is 25 years and HbA(1c) level is 7%, the cost-effectiveness ratio is USD 39,530 per QALY. CONCLUSION This model, with its underlying assumptions and data, suggests that early treatment with captopril provides modest benefit at reasonable cost effectiveness, from the US single-payer perspective, in the prevention of ESRD compared with delaying treatment until diagnosis of microalbuminuria. Early treatment with other ACE inhibitors will provide similar cost effectiveness if they have equivalent efficacy, compliance and price per dose. Treatment may be considered among patients at age 20 years with new onset of type 1 diabetes. This conclusion is sensitive to the extent that ACE inhibitors delay onset of microalbuminuria. Other factors such as the patient's age and glycaemic level must be considered when deciding to initiate early treatment.
Collapse
Affiliation(s)
- Frederick B Dong
- Battelle, Centers for Public Health Research and Evaluation, Seattle, Washington, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Velasquez MT, Striffler JS, Abraham AA, Michaelis OE, Scalbert E, Thibault N. Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. Hypertension 1997; 30:1232-7. [PMID: 9369281 DOI: 10.1161/01.hyp.30.5.1232] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We compared the effects of long-term treatment with the angiotensin-converting enzyme inhibitor perindopril and triple therapy (hydrochlorothiazide, reserpine, and hydralazine) on the metabolic and renal features in the SHR/N-corpulent (cp) rat, a genetic model of non-insulin-dependent diabetes mellitus and hypertension. Obese male SHR/N-cp rats (4 to 6 weeks old) were fed a 54% carbohydrate diet containing 18% sucrose and 36% starch. After 2 months on the diet, rats were assigned to one of three groups: one group (n=8) received perindopril (PE); the second group (n=8) received triple therapy (TT); and the third group (n=8) did not receive therapy. Treatment was maintained for 3 to 4 months. Body weight, food intake, and fasting levels of serum glucose and insulin did not differ among the three groups. Control rats exhibited progressive proteinuria in parallel with the rise in systolic blood pressure (SBP). Both PE and TT equally lowered SBP to normal levels and reduced proteinuria in treated rats. However, the reduction of proteinuria was greater and more sustained with PE than with TT (P<.05), whereas the effect of TT on proteinuria was delayed. Plasma renin activity was increased in PE and TT rats compared with control rats (P<.02). Semiquantitative analysis of renal lesions showed that the percentage of glomeruli with mesangial expansion and sclerosis and the tubulointerstitial score (an index of severity of tubulointerstitial lesions, namely tubular atrophy, inflammatory cellular infiltrates, and interstitial fibrosis) was reduced in both PE and TT rats. However, the reduction of glomerulosclerosis and tubulointerstitial lesions was greater in PE than in TT rats (P<.01). The percentage of glomerular sclerosis was positively correlated with the severity score of tubulointerstitial lesions (r=.60, P<.01). We conclude that PE is more effective than TT in halting the progression of proteinuria in the SHR/N-cp rat with non-insulin-dependent diabetes mellitus and hypertension. The antiproteinuric effect of PE is associated with significant reduction in glomerulosclerosis and tubulointerstitial lesions, independent of the effect of treating hypertension.
Collapse
Affiliation(s)
- M T Velasquez
- Department of Medicine, George Washington University Medical Center, Washington, DC 20037, USA
| | | | | | | | | | | |
Collapse
|
5
|
Bretzel RG. Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy. J Diabetes Complications 1997; 11:112-22. [PMID: 9101397 DOI: 10.1016/s1056-8727(96)00105-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Diabetic nephropathy is the major cause of illness and premature death in people with diabetes, largely through accompanying cardiovascular disease and end-stage renal failure. Diabetic patients are several times as prone to kidney disease as nondiabetic people and the accumulative risk of diabetic nephropathy in insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) is about 30%-50% after 25 years of disease. Diabetic nephropathy is a progressive disease that takes several years to develop, ending in chronic renal insufficiency. Proteinuria heralds the onset of diabetic nephropathy, and the worsening of proteinuria parallels the progression of renal disease. The main risk factors for the frequency, severity, and progression of diabetic nephropathy are the degree of hyperglycemia and associated metabolic disturbances, hypertension, protein overload, cigarette smoking, as well as the duration of diabetes. Interventional strategies for primary, secondary, and tertiary prevention of diabetic nephropathy therefore include meticulous glycemic control, appropriate treatment of associated lipid abnormalities, rigorous control of the blood pressure, reduction in dietary protein intake, in particular animal protein, and of fat intake, and stopping cigarette smoking. Randomized clinical trials indicate that antihypertensive therapy is beneficial in preventing and slowing down the progression of diabetic nephropathy. There is now increasing evidence that angiotensin-converting enzyme inhibitors and certain calcium antagonists produce a more beneficial effect on diabetic nephropathy in terms of reducing proteinuria and slowing the progression to diabetic renal failure. These drugs are attributed nephroprotective capacity beyond their blood pressure lowering capacity and initial clinical trials with combinations have revealed even additive protective effects on end organs.
Collapse
Affiliation(s)
- R G Bretzel
- Third Medical Department, University of Giessen, Germany
| |
Collapse
|
6
|
Bretzel RG. Can we further slow down the progression to end-stage renal disease in diabetic hypertensive patients? JOURNAL OF HYPERTENSION. SUPPLEMENT : OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF HYPERTENSION 1997; 15:S83-8. [PMID: 9218204 DOI: 10.1097/00004872-199715022-00008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
HYPERTENSION AND DIABETES Hypertension occurs about twice as frequently in diabetics compared with the general population, with a prevalence of approximately 25% in young patients with insulin-dependent diabetes mellitus (IDDM) and 50% in newly diagnosed non-IDDM (NIDDM) patients. Studies strongly suggest that hypertensions is involved in the progression and perhaps the onset of diabetic nephropathy, which is a major cause of illness and premature death in diabetic patients, largely through accompanying cardiovascular disease and end-stage renal failure. TREATMENT A large body of evidence has accumulated which emphasizes the beneficial effects of antihypertensive treatment in reducing proteinuria and preserving renal function in both IDDM and NIDDM. It appears that angiotensin converting enzyme inhibitors and certain calcium antagonists, notably the non-dihydropyridine type and second-generation dihydropyridine calcium antagonists, produce a more beneficial effect on nephropathy in terms of reducing proteinuria and slowing progression in renal failure. These drugs have displayed a nephroprotective capacity beyond their systemic blood pressure-lowering effects, and initial clinical trials with combinations of different antihypertensive drug classes have revealed additive effects in reducing albuminuria together with the lowest rate of decline in glomerular filtration rates with the lowest incidence of adverse effects. AVAILABLE STUDIES The studies available on antihypertensive treatment in IDDM and NIDDM patients with incipient or overt diabetic nephropathy are mainly prospective. There have also been some preliminary trials with antihypertensive combinations in diabetic patients.
Collapse
Affiliation(s)
- R G Bretzel
- Third Medical Department, Justus-Liebig University, Giessen, Germany
| |
Collapse
|
7
|
Thakkar H, Newman DJ, Holownia P, Davey CL, Wang CC, Lloyd J, Craig AR, Price CP. Development and validation of a particle-enhanced turbidimetric inhibition assay for urine albumin on the Dade aca® analyzer. Clin Chem 1997. [DOI: 10.1093/clinchem/43.1.109] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
AbstractThe measurement of urine albumin now has a well-established role in the monitoring of patients with diabetes mellitus. We have developed a particle-enhanced immunoturbidimetric inhibition assay for urine albumin on the Dade aca® analyzer. The inhibition approach removes any of the potential antigen excess difficulties that could be expected from the wide clinical range of urine albumin, but retains the sensitivity advantages of latex-enhanced immunoturbidimetry. Human serum albumin (HSA) is covalently attached to 40-nm poly(chloromethyl)styrene-modified latex particles. This reagent, along with monoclonal antibody to HSA, is aliquoted into the aca reagent pack along with polyethylene glycol 8000 in a tablet form (giving a final reaction concentration of 15 g/L). A 150 mmol/L phosphate buffer, pH 7.8, is used to fill the reagent pack in the instrument and the agglutination reaction is monitored at 340 nm. The sample volume is 100 μL and the calibration curve covers the range 2–250 mg/L. Evaluation of commercial scale reagents against the Beckman Array nephelometric immunoassay system gave a Deming regression correlation of aca = 0.87 × Beckman + 8.5,r = 0.995, n = 145. Mean analytical recovery was 104 ± 4.5%, n = 20, and there was no evidence of a lack of parallelism. Interassay precision was 8.8% at 10.0 mg/L and <2.5% at >65 mg/L. Calibrator stability was in excess of 60 days. A small reference range study (24-h urine collections, n = 27) gave a mean of 5.6 mg/L with a range of 0.5–16.2 mg/L. Analytical sensitivity (2.5 SD from zero) was 0.40 mg/L.
Collapse
Affiliation(s)
- Hansa Thakkar
- Department of Clinical Biochemistry, St Bartholomew’s and the Royal London School of Medicine and Dentistry, Turner Street, London E1 2AD, UK
| | - David J Newman
- Department of Clinical Biochemistry, St Bartholomew’s and the Royal London School of Medicine and Dentistry, Turner Street, London E1 2AD, UK
| | - Peter Holownia
- Department of Clinical Biochemistry, St Bartholomew’s and the Royal London School of Medicine and Dentistry, Turner Street, London E1 2AD, UK
| | - Carol L Davey
- Department of Clinical Biochemistry, St Bartholomew’s and the Royal London School of Medicine and Dentistry, Turner Street, London E1 2AD, UK
| | | | - Joseph Lloyd
- Glasgow site, Dade International, Wilmington, DE
| | - Alan R Craig
- Glasgow site, Dade International, Wilmington, DE
| | - Christopher P Price
- Department of Clinical Biochemistry, St Bartholomew’s and the Royal London School of Medicine and Dentistry, Turner Street, London E1 2AD, UK
| |
Collapse
|
8
|
Hansen KW. Ambulatory blood pressure in insulin-dependent diabetes: the relation to stages of diabetic kidney disease. J Diabetes Complications 1996; 10:331-51. [PMID: 8972385 DOI: 10.1016/s1056-8727(96)00065-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- K W Hansen
- Medical Department M, Aarhus Kommunehospital, Denmark
| |
Collapse
|
9
|
Mogensen CE. Microalbuminuria in prediction and prevention of diabetic nephropathy in insulin-dependent diabetes mellitus patients. J Diabetes Complications 1995; 9:337-49. [PMID: 8573761 DOI: 10.1016/1056-8727(95)80036-e] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- C E Mogensen
- Medical Department M, Aarhus Kommunehospital, Denmark
| |
Collapse
|
10
|
Barnes DJ, Viberti GC. Strategies for the prevention of diabetic kidney disease: early antihypertensive treatment or improved glycemic control? J Diabetes Complications 1994; 8:189-92. [PMID: 8086658 DOI: 10.1016/1056-8727(94)90040-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- D J Barnes
- Unit for Metabolic Medicine, United Medical and Dental Schools, Guy's Hospital, London, England
| | | |
Collapse
|
11
|
Abstract
The development in recent years of sensitive assays specific for albumin has facilitated extensive investigation of the pathophysiology and clinical significance of microalbuminuria. It is now clear that the appearance of microalbuminuria represents a crucial event in the natural histories of diabetes mellitus and essential hypertension. It reflects the presence of generalized vascular damage and is strongly predictive of subsequent renal failure, cardiovascular morbidity, and death. Therapeutic interventions, including strict diabetic and blood-pressure control, can reduce microalbuminuria and improve the overall prognosis. The detection and treatment of microalbuminuria in these high-risk groups should now form an integral part of their management. Large-scale screening programmes are also recommended for insulin-dependent diabetics.
Collapse
|
12
|
Adamson CL, Kumar S, Sutcliffe H, France MW, Boulton AJM. Screening strategies in the detection of microalbuminuria in insulin-dependent diabetic patients. ACTA ACUST UNITED AC 1993. [DOI: 10.1002/pdi.1960100408] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
13
|
Mogensen CE, Hansen KW, Nielsen S, Pedersen MM, Rehling M, Schmitz A. Monitoring diabetic nephropathy: glomerular filtration rate and abnormal albuminuria in diabetic renal disease--reproducibility, progression, and efficacy of antihypertensive intervention. Am J Kidney Dis 1993; 22:174-87. [PMID: 8322781 DOI: 10.1016/s0272-6386(12)70184-1] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The principal end point in the evaluation of treatment in incipient and overt diabetic nephropathy is rate of decline in glomerular filtration rate (GFR). Therefore, information on reproducibility of GFR measurements is essential in the planning and evaluation of clinical trials. We studied reproducibility of GFR measurements in insulin-dependent and non-insulin-dependent diabetes mellitus patients using, respectively, a constant-infusion technique with urine collection and labeled iothalamate as a tracer marker and a single-shot procedure using Cr-EDTA, measuring the GFR from the decline in plasma level after bolus injection. The coefficient of variance in the insulin-dependent patients was from 7.5% to 8.8% with repeated measurements. In longitudinal studies with several measurements the mean coefficient of variances varied between 7.4% and 3.4%. In the non-insulin-dependent patients the coefficient of variances between two tests were 7.0% and 5.3% for normoalbuminuric and microalbuminuric patients, respectively. In cross-sectional studies as well as in longitudinal studies, it has been consistently shown that GFR is well preserved and at a supranormal level in patients with normoalbuminuria and microalbuminuria. A decline in GFR appears to start around the transition from microalbuminuria to overt diabetic renal disease, although more detailed studies are needed to support this finding. With regard to intervention trials, several studies document that microalbuminuria can be reduced by effective antihypertensive treatment, particularly with angiotensin-converting enzyme inhibitors, also in patients with normal or close to normal blood pressure. Preliminary results from long-term studies suggest that reduction in microalbuminuria in these patients is associated with preservation of GFR and, thus, apparently renoprotection. In patients with overt renal disease, it has been consistently shown that antihypertensive treatment reduces albuminuria as well as the rate of decline in GFR. This is also observed with combined treatment regimens, for instance beta blockers or angiotensin-converting enzyme inhibitors combined with diuretics, or the three types of drugs in combination.
Collapse
Affiliation(s)
- C E Mogensen
- Medical Department of Diabetes and Endocrinology, Aarhus Kommunehospital, University Hospitals, Denmark
| | | | | | | | | | | |
Collapse
|
14
|
Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ (CLINICAL RESEARCH ED.) 1993; 306:1722-5. [PMID: 8343628 PMCID: PMC1678304 DOI: 10.1136/bmj.306.6894.1722] [Citation(s) in RCA: 90] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
OBJECTIVE To analyse the cost-benefit of screening for and antihypertensive treatment of early renal disease indicated by microalbuminuria in patients with insulin dependent diabetes mellitus. DESIGN Previously published data were used to estimate transition probabilities for each step from normoalbuminuria until death. The effect of intervention on urinary albumin excretion rate by antihypertensive treatment was arbitrarily set at three different levels. All direct costs (screening, antihypertensive treatment, treatment of end stage renal failure) were included in the cost-benefit analysis by using real discount rates of 2.5% and 6%. SETTING Computer simulation. SUBJECTS Simulated cohort of 8000 patients. MAIN OUTCOME MEASURES Mortality, incidence of diabetic nephropathy, incidence of end stage renal failure, and costs versus savings. RESULTS Assuming treatment effects of 33% and 67% median life expectancy increased by four to 14 years, respectively, and the need for dialysis or transplantation decreased by 21% to 63%. Costs and savings would balance if the annual rate of increase of albuminuria was decreased from 20% to 18% a year. CONCLUSIONS Screening and intervention programmes are likely to have life saving effects and lead to considerable economic savings.
Collapse
Affiliation(s)
- K Borch-Johnsen
- Institute of Preventive Medicine, Kommunehospitalet, Copenhagen K, Denmark
| | | | | | | |
Collapse
|
15
|
Lacourcière Y, Nadeau A, Poirier L, Tancrède G. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 1993; 21:786-94. [PMID: 8500859 DOI: 10.1161/01.hyp.21.6.786] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The effects of long-term treatment with captopril and conventional therapy on albuminuria and metabolic parameters were compared in 74 hypertensive type II diabetics with normal serum creatinine. Patients were treated double-blind with either captopril monotherapy or combined with hydrochlorothiazide or therapy with metoprolol, hydrochlorothiazide, or both for 36 months. The treatment was titrated to achieve goal diastolic blood pressure of < or = 85 mm Hg. The reductions in blood pressures during treatment were similar in patients with (n = 21) and without (n = 53) microalbuminuria treated with either captopril or conventional therapy. No significant changes in albuminuria occurred in normoalbuminuric patients with either therapy. Although albuminuria fell in nearly all patients with microalbuminuria treated with captopril, it rose in eight of 12 patients on conventional therapy, with macroalbuminuria developing in two of them. Renal function was preserved by both types of treatment in both patient groups. Long-term treatment with either conventional therapy or captopril did not alter metabolic variables. We conclude that captopril alone or in combination decreases albuminuria and prevents the development of macroalbuminuria in hypertensive type II diabetics with persistent microalbuminuria. The renoprotective effect of this agent, however, remains to be demonstrated with longer term data on renal function. Aggressive antihypertensive treatment with either captopril or conventional therapy appears to be effective in preventing the onset of microalbuminuria in most normoalbuminuric patients. In contrast, with previous short-term studies, the use of converting enzyme inhibitors or conventional therapy did not cause adverse metabolic effects.
Collapse
Affiliation(s)
- Y Lacourcière
- Hypertension Research Unit, CHUL Research Center, Centre Hospitalier de l'Université Laval, Ste-Foy, Quebec, Canada
| | | | | | | |
Collapse
|
16
|
Rudberg S, Sätterström G, Dahlqvist R, Dahlquist G. Indomethacin but not metoprolol reduces exercise-induced albumin excretion rate in type 1 diabetic patients with microalbuminuria. Diabet Med 1993; 10:460-4. [PMID: 8334827 DOI: 10.1111/j.1464-5491.1993.tb00099.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The effects of a single oral dose of indomethacin (1 mg kg-1) metoprolol (1.5 mg kg-1) and placebo on exercise-induced albumin excretion rate (AER) were compared in a randomized, crossover design in 14 normotensive, young Type 1 diabetes patients, nine of them with microalbuminuria (AER > 15 micrograms min-1) and five without microalbuminuria at rest. The albumin excretion rate, blood pressure, heart rate, blood glucose, and plasma concentrations of indomethacin and metoprolol were determined before and after 30 min submaximal physical exercise. In microalbuminuric patients the rise in albumin excretion rate after exercise on indomethacin (7 micrograms min-1) was lower than after placebo (29 micrograms min-1, p < 0.001) whereas the rise in albumin excretion rate with metoprolol during exercise (18 micrograms min-1) did not differ from placebo (p = 0.48), in spite of the expected less marked increase in blood pressure. In normoalbuminuric patients no significant increase in albumin excretion rate was noted by exercise in any of the treatment periods. A tendency to a linear correlation (r = -0.54, p = 0.07) was seen between the plasma concentration of indomethacin and the inhibition of exercise-induced increase in albumin excretion rate. No correlations were observed between exercise-induced changes in albumin excretion rate and systolic blood pressure, heart rate or blood glucose. In conclusion, acute indomethacin treatment, presumably through inhibition of renal prostaglandin synthesis, reduces the exercise-induced rise in albumin excretion rate in Type 1 diabetic patients with microalbuminuria.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- S Rudberg
- Department of Paediatrics, Karolinska Institute, St. Görans Hospital, Stockholm, Sweden
| | | | | | | |
Collapse
|
17
|
Affiliation(s)
- A B Ribeiro
- Division of Nephrology, Escola Paulista de Medicina, São Paulo, Brazil
| |
Collapse
|
18
|
Abstract
The UK Prospective Diabetes Study (UKPDS) is a multi-centre, prospective, randomised, intervention trial of 5100 newly-diagnosed patients with Type 2 (non-insulin-dependent) diabetes mellitus which aims to determine whether improved blood glucose control will prevent complications and reduce the associated morbidity and mortality. Newly presenting Type 2 diabetic patients aged 25-65 years inclusive, median age 53 years, median body mass index 28 kg/m2 and median fasting plasma glucose 11.3 mmol/l, were recruited and treated initially by diet. Ninety five percent remained hyperglycaemic (fasting plasma glucose greater than 6 mmol/l) and were randomly allocated to different therapies. In the main randomisation, those who were asymptomatic and had fasting plasma glucose under 15 mmol/l were allocated either to diet policy, or to active policy with either insulin or sulphonylurea aiming to reduce the fasting plasma glucose to under 6 mmol/l. Over 3 years, the median fasting plasma glucose in those allocated to diet policy was 8.9 mmol/l compared with 7.0 mmol/l in those allocated to active policy. The Hypertension in Diabetes Study has been included in a factorial design to assess whether improved blood pressure control will be advantageous. Patients with blood pressure greater than or equal to 160/90 mm Hg were randomly allocated to tight control aiming for less than 150/85 mm Hg with either an angiotensin-converting enzyme inhibitor or a Beta-blocker or to less tight control aiming for less than 200/105 mm Hg. The endpoints of the studies are major clinical events which affect the life and well-being of patients, such as heart attacks, angina, strokes, amputations, blindness and renal failure. To date, 728 patients have had at least one clinical endpoint. Surrogate endpoints include indices of macrovascular and microvascular disease detected by ECG with Minnesota Coding, retinal colour photography and microalbuminuria. The studies also aim to evaluate potential risk factors for the development of diabetic complications such as smoking, obesity, central adiposity, plasma LDL- and HDL-cholesterol, triglyceride, insulin, urate and other biochemical variables. The studies are planned to terminate in 1994, with a median follow-up of 9 years (range 3-16 years) for the glucose study and 5 years (range 2-6 years) for the hypertension study.
Collapse
|
19
|
McHardy KC, Gann ME, Ross IS, Pearson DW. A simple approach to screening for microalbuminuria in a type 1 (insulin-dependent) diabetic population. Ann Clin Biochem 1991; 28 ( Pt 5):450-5. [PMID: 1958047 DOI: 10.1177/000456329102800505] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The reproducibility of albumin concentration in first-morning samples of urine was assessed in 334 insulin-dependent diabetic patients aged 18-60 years. The albumin excretion rate was determined immunoturbidimetrically in three sterile, Albustix-negative, first-morning urine samples submitted over a week. An abnormally high mean value, greater than or equal to 2.5 mg albumin per mmol creatinine (Ua/Uc), was found in 33 patients (9.9%). These patients were older (mean 42 vs 34 years, P less than 0.01), had longer disease duration (18 vs 14 years, P less than 0.01) and higher HbA1c values (6.8 vs 6.3%, P less than 0.05) than those without microalbuminuria. Although triplicate samples were collected within 7 days, Ua/Uc showed considerable intraindividual variation, with a mean coefficient of variation of 49%. Despite this it was found that Ua/Uc values greater than 1 mg/mmol on the first specimen had a sensitivity of 97% and a specificity of 82% for detecting those with a three-sample mean value greater than 2.5 mg/mmol. Thus virtually all those with microalbuminuria (32/33) had a single first-morning result greater than 1 mg/mmol, and in those with a lower ratio microalbuminuria was excluded with more than 99% certainty.
Collapse
Affiliation(s)
- K C McHardy
- Department of Medicine & Therapeutics, Aberdeen, UK
| | | | | | | |
Collapse
|
20
|
Abstract
Approximately 6 million people in the United States are known to be diabetic, with an estimated 4 million individuals having undiagnosed diabetes mellitus. The metabolic derangements of both insulin-dependent diabetes mellitus (IDDM) and noninsulin-dependent diabetes mellitus (NIDDM) result in widespread end-organ damage, including progressive kidney failure. Since its initial description in 1936, the incidence of diabetic nephropathy has progressively increased, and it is now the most common cause of newly diagnosed end-stage renal disease (ESRD) requiring renal replacement therapy in the United States. While basic research efforts into pathogenesis continue, there is significant interest in clinical interventions that may slow the progression of diabetic renal disease. In addition, the options available for renal replacement therapy have increased and improved substantially in recent years.
Collapse
|
21
|
|
22
|
Seefeldt T, Orskov L, Mengel A, Rasmussen O, Pedersen MM, Møller N, Christiansen JS, Schmitz O. Lack of effects of angiotensin-converting enzyme (ACE)-inhibitors on glucose metabolism in type 1 diabetes. Diabet Med 1990; 7:700-4. [PMID: 2147631 DOI: 10.1111/j.1464-5491.1990.tb01473.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
To evaluate the impact of ACE-inhibitors on insulin-mediated glucose uptake, glucose-induced glucose uptake, and hepatic glucose production, a sequential glucose clamp was performed in eight normotensive Type 1 diabetic patients after 3 weeks of enalapril therapy 20 mg day-1 and during control conditions. The experiments were carried out in random order. Mean arterial blood pressure was significantly reduced during ACE-inhibition (95 +/- 3 (+/- SE) vs 84 +/- 3 mmHg; p less than 0.02), while blood glucose control as assessed by HbA1c was unaltered (7.9 +/- 0.5 vs 7.6 +/- 0.5%). The night prior to the study normoglycaemia was maintained by a Biostator. A two-step hyperinsulinaemic euglycaemic clamp (insulin infusion rate 0.3 and 0.8 mU kg-1 min-1) was followed by a hyperinsulinaemic and hyperglycaemic clamp (insulin infusion rate 0.8 mU kg-1 min-1, plasma glucose 11 mmol l-1). Insulin concentrations were comparable with and without enalapril treatment. During the hyperinsulinaemic clamps isotopically determined glucose disposal was unchanged (low dose 2.5 +/- 0.3, high dose 4.3 +/- 0.7 vs 2.6 +/- 0.3 and 4.3 +/- 0.7 mg kg-1 min-1, enalapril vs control). Glucose-induced glucose disposal (9.2 +/- 1.2 vs 9.1 +/- 1.2 mg kg-1 min-1) was also similar, as were non-protein respiratory exchange ratios (indirect calorimetry). Glucose production was not changed by enalapril. In conclusion, treatment with enalapril has no significant effect on glucose metabolism in Type 1 diabetes.
Collapse
Affiliation(s)
- T Seefeldt
- Department of Medicine M, Randers Centralsygehus, Second University Clinic of Internal Medicine, Aarhus Kommunehospital, Denmark
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Christensen CK, Pedersen MM, Mogensen CE. Combining antihypertensive agents in early diabetic nephropathy. THE JOURNAL OF DIABETIC COMPLICATIONS 1990; 4:88-90. [PMID: 2145311 DOI: 10.1016/0891-6632(90)90044-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- C K Christensen
- Second University Clinic of Internal Medicine, Aarhus kommunehospital, Denmark
| | | | | |
Collapse
|
24
|
Affiliation(s)
- J C Townsend
- Department of Clinical Chemistry, Royal Hallamshire Hospital, Sheffield, England
| |
Collapse
|
25
|
|
26
|
Viberti GC. Interventions based on microalbuminuria screening and low-protein diet in the treatment of kidney disease of diabetes mellitus. Am J Kidney Dis 1989; 13:41-4. [PMID: 2643309 DOI: 10.1016/s0272-6386(89)80114-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Microalbuminuria in insulin-dependent diabetics appears to indicate early renal damage rather than susceptibility to it, yet a series of relatively small, short-term intervention studies in insulin-dependent diabetes mellitus patients have already demonstrated reduction in albumin excretion rates or arrest in the increase of fractional clearance of albumin. Treatments have ranged from the use of angiotensin-converting enzyme inhibitors aimed at lowering BP to the use of diets restricted to 0.5 to 0.6 g/kg protein and strict blood glucose control by intensified insulin treatment. Large, long-term intervention studies of cohorts of insulin-dependent and non-insulin-dependent diabetic patients with microalbuminuria are now needed to assess the effects of the different modalities of care on the development of persistent proteinuria, end-stage renal disease, and cardiovascular mortality as well as associated quantitative changes in the renal structure.
Collapse
Affiliation(s)
- G C Viberti
- Unit for Metabolic Medicine, UMDS, Guy's Hospital, London, England
| |
Collapse
|
27
|
Mogensen CE, Schmitz O. The diabetic kidney: from hyperfiltration and microalbuminuria to end-stage renal failure. Med Clin North Am 1988; 72:1465-92. [PMID: 3054363 DOI: 10.1016/s0025-7125(16)30717-9] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
This article describes many new concepts within the area of diabetic renal involvement and diabetic renal disease. Considerable progress has taken place within this area, not only regarding diagnosis of early diabetic nephropathy but also the early treatment of nephropathy in its incipient stage.
Collapse
Affiliation(s)
- C E Mogensen
- Second University Clinic of Internal Medicine, Kommunehospitalet, Aarhus, Denmark
| | | |
Collapse
|
28
|
Mogensen CE, Schmitz A, Christensen CK. Comparative renal pathophysiology relevant to IDDM and NIDDM patients. DIABETES/METABOLISM REVIEWS 1988; 4:453-83. [PMID: 3061756 DOI: 10.1002/dmr.5610040504] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Hyperfiltration is a very characteristic feature in insulin-dependent diabetes. Hyperfiltration is to some extent associated with long-term glycemic control but the correlation is not very strong. Long-term hyperfiltration may play a role in the genesis of late diabetic nephropathy, but it is difficult to distinguish effects of hyperfiltration per se from effects of poor metabolic control. Long-term hyperfiltration without diabetes does not produce nephropathy. It is hypothesized that IDDM patients who do not show considerable hyperfiltration in spite of poor metabolic control may be those who are to some extent protected against late diabetic nephropathy, but other mechanisms may also be involved in the renal protection of these patients, who survive long-term diabetes without nephropathy. On the other hand, those with poor metabolic control combined with hyperfiltration are likely to develop nephropathy. In addition, it is suggested that the metabolic aberrations in diabetes, with the subsequent changes in the biochemistry of the glomerular wall, are permissive and absolutely required for the development of diabetic nephropathy. Of note, diabetic glomerulopathy in NIDDM occurs without significant hyperfiltration and extreme hyperfiltration in the one-kidney-model (without diabetes) does not produce nephropathy. Nonglycemic modalities of intervention, resulting in reduced hyperfiltration, e.g., low-protein diet or administration of somatostatin analogues, deserves interest as new potential ways of preventing or postponing diabetic nephropathy. Also intervention with aldose-reductase inhibitors may be an important therapeutic modality for those patients in whom good metabolic control is not obtainable. It is now well-established that antihypertensive treatment, including ACE-inhibition, reduces rate of decline in GFR in patients with already established nephropathy. In addition, protein excretion is diminished in IDDM patients with incipient diabetic nephropathy by antihypertensive treatment where GFR is well-preserved during treatment. No data are available for NIDDM.
Collapse
Affiliation(s)
- C E Mogensen
- Medical Department M, Second University Clinic of Internal Medicine, Kommunehospitalet, Aarhus, Denmark
| | | | | |
Collapse
|
29
|
Affiliation(s)
- C E Mogensen
- Second University Clinic of Internal Medicine, Kommunehospitalet, Aarhus C, Denmark
| |
Collapse
|